Senior Leadership

高层领导

基本信息

批准号：
7529410
负责人：
FRANK M. TORTI
金额：
$ 18.77万
依托单位：
WAKE FOREST UNIVERSITY HEALTH SCIENCES
依托单位国家：
美国
项目类别：
财政年份：
2007
资助国家：
美国
起止时间：
2007-07-11 至 2012-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7529410
关键词：
Advisory Committees American Appointment Area Biomedical Research Cancer Center Cellular biology Clinic Clinical Clinical Oncology Clinical Research Clinical and Translational Science Awards Comprehensive Cancer Center DNA Repair Decision Making Director&apos s Working Group Early Diagnosis Foxes Funding Health system Hematology Hematopoietic Hospitals Immune Iowa Ireland Joints Leadership Letters Malignant Neoplasms Medical Names Operative Surgical Procedures Paper Patient Care Peer Review Physicians Process Publishing Radiation Rapid Access to Intervention Development Research Research Institute Research Priority Resource Sharing Resources Services Site Stem cells Strategic Planning Study Section Text Therapeutic Studies Time United States National Institutes of Health University Hospitals anticancer research authority cancer research center director drug development gene therapy medical schools member oncology professor programs

项目摘要

SENIOR LEADERSHIP Stanton L. Gerson, MD, Director, Case Comprehensive Cancer Center (Case CCC) Dr. Gerson was named Director of the Case Comprehensive Cancer Center and Associate Dean for Oncology in September, 2004. Qualifications: Dr. Gerson was Program Leader for the Hematopoietic and Immune Cell Biology Program from 1992-2004, and Associate Director for Clinical Research from 1995-2004. He was promoted to tenured Professor in 1993, was named the Shiverick Professor for Hematological Oncology in 1997, and elected to the American Association of Physicians in 1997. Dr. Gerson became the Chief of the Division of Hematology-Oncology in 1995. Dr. Gerson has provided extensive service to the NIH peer review process, serving as ad hoc reviewer since 1989, on the Experimental Therapeutics study section from 1997-2002 (Chair from 2000-2002); the RAID program SAB from 2001-2005; Subcommittee D for the Program Projects study section (2004-); and the NCI external review for the NCI-RAID program in 2005 . He currently chairs the Early Detection Subcommittee for the NCI Cancer Center Directors Working Group chaired by John Mendelsohn, MD, to provide guidance to the NCI on the 2015 initiative. Dr. Gerson has published over 175 peer-reviewed papers, and co-edited 2 texts, Gene Therapy of Cancer (1999, 2002) and Clinical Hematology (2005). Dr. Gerson serves on the External Advisory Committees for the Fox Chase Comprehensive Cancer Center, the Kimmel Johns Hopkins Comprehensive Cancer Center, and the Iowa Comprehensive Cancer Center. He spends 50% of his time administering the Comprehensive Cancer Center, 35% effort on his research, 10% effort administering the Ireland Cancer Center, and 5% effort on patient care. Research Accomplishments: Dr. Gerson's research has focused on three related areas: stem cell biology, DNA repair, and drug development related to DNA repair as a target. He has been continuously funded by the NIH since 1984. Details of these activities are described in the Overview, section 6.7. Authority: As Director, Dr. Gerson has authority to approve and review membership including Senior and Program Leaders to the Case CCC. He can make primary appointments to the Center, and with Cancer Center resources, facilitate recruitments to many primary departments of Case School of Medicine and to Clinical Departments of University Hospitals of Cleveland. He has the responsibilities of a Department Chair at both Case School of Medicine and University Hospitals of Cleveland. He also actively participates in research administrative activities at Lerner Research Institute and Taussig Cancer Center by participating directly on their search committees, and through the Senior Leadership Committee of the Cancer Center, which includes the Associate Director for the Lerner Research Institute and the Associate Director for the Taussig Cancer Center, in setting the cancer research priorities of members and programs of the Cleveland Clinic. This is further defined in the joint institutional leadership letter. Dr. Gerson has fiscal and administrative authority over all Shared Resources of the Case CCC, 47,000 sq ft of research space in the Wolstein Building, shared resource space in the Biomedical Research Building and Sears Tower Building of the Case School of Medicine, research administrative space in the Wearn Building of University Hospitals of Cleveland, the clinical oncology space and services (medical, radiation and surgical) of University Hospitals of Cleveland and the Ireland Cancer Center sites of University Hospital Health System. In addition, Dr. Gerson serves on the Steering Committee of the Cleveland Clinical & Translational Science Award (CTSA) application submitted by Case and including the affiliated hospitals in March 2006. Dr. Gerson convenes the External and Internal Advisory Boards of the Case CCC and with their advice, makes decisions on Programs, Shared Resources and strategic planning for the Center.

高级领导病例综合癌症中心主任Stanton L. Gerson医学博士（CASE CCC）格森博士被任命为案件综合癌症中心和副院长用于2004年9月的肿瘤学。资格：Gerson博士是造血和免疫细胞生物学的计划负责人 1992 - 2004年的计划，以及1995 - 2004年的临床研究副总监。他是 1993年晋升为终身教授，被任命为颤抖的血液学教授 1997年，并于1997年当选为美国医师协会。 1995年血液学 - 肿瘤学系。Gerson博士为NIH同伴提供了广泛的服务自1989年以来，在实验治疗研究部分就担任临时审阅者的审查过程从1997年至2002年（2000- 2002年的主席）； RAID计划SAB 2001- 2005年；小组委员会D 计划项目研究部分（2004-）;以及2005年NCI-RAID计划的NCI外部审查。他目前担任NCI癌症中心主管工作组的早期检测小组委员会由医学博士John Mendelsohn主持，为NCI提供了2015年倡议的指导。格森博士有发表了超过175份同行评审的论文，并共同编辑了2条癌症基因治疗（1999，2002）和临床血液学（2005）。格森博士在福克斯的外部咨询委员会任职大通综合癌症中心，金梅尔·约翰·霍普金斯综合癌症中心和爱荷华州综合癌症中心。他花了50％的时间管理综合癌症中心，他的研究努力35％，在爱尔兰癌症中心进行10％的努力和5％为患者护理而努力。研究成就：Gerson博士的研究重点是三个相关领域：STEM 与DNA修复有关的细胞生物学，DNA修复和药物开发。他曾经自1984年以来一直由NIH资助。这些活动的详细信息在概述中描述了第6.7节。当局：作为董事，格森博士有权批准和审查会员资格案件CCC的高级和计划负责人。他可以任命为中心的主要任命，并且有了癌症中心资源，便利地招募了案例学校的许多小学系医学和克利夫兰大学医院的临床系。他有一个克利夫兰的案例医学院和大学医院的系主任。他也是积极参加Lerner研究所和Taussig Cancer的研究行政活动通过直接参加搜索委员会以及高级领导委员会的中心癌症中心，其中包括Lerner研究所副主任和 Taussig癌症中心副主任，确定成员的癌症研究重点克利夫兰诊所的计划。这在联合机构领导信中进一步定义了这一点。博士 Gerson对CCC的所有共享资源具有财政和行政权限，47,000平方英尺沃尔斯坦大楼的研究空间，生物医学研究大楼中的资源空间和案例医学院的西尔斯塔楼大楼，磨损的研究行政空间克利夫兰大学医院建造临床肿瘤空间和服务（医疗，辐射克利夫兰大学和爱尔兰癌症中心的大学医院的外科医院医院卫生系统。此外，格森博士在克利夫兰指导委员会任职案例提交的临床与转化科学奖（CTSA）申请，包括附属医院于2006年3月。格森博士召集了该案的外部和内部咨询委员会 CCC及其建议，就计划，共享资源和战略计划做出决定中心。